Syros Pharmaceuticals (SYRS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SYRS Syros Pharmaceuticals

Watchlist

2.7300
-0.5000-15.48%

Close Nov 12 16:00 ET

0.3700
-2.3600-86.45%

Post 18:49 ET

73.25MMarket Cap-889P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Syros's Tamibarotene Fails Phase 3 Study, Triggering Possible Loan Default
Seeking Alpha17:03 ET
Syros Pharmaceuticals Trading Resumes
TipRanks17:00 ET
Syros Pharmaceuticals Says SELECT-MDS-1 Trial Did Not Meet Primary Endpoint
TipRanks16:41 ET
Express News | Syros Pharmaceuticals Inc - to Discontinue Study and Review Full Data Set
Reuters16:31 ET
Express News | Syros Pharmaceuticals Inc - -- Select-Mds-1 Did Not Meet Its Primary Endpoint
Reuters16:31 ET
Express News | Syros Announces Topline Data From Select-Mds-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome With Rara Gene Overexpression
Reuters16:30 ET

Comments

Trytosaveabit

2 hours ago

News

$Syros Pharmaceuticals (SYRS.US)$ Reuters· 1 min ago1min
Syros Announces Topline Data From Select-Mds-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome With Rara Gene Overexpression! Did not meet endpoint!

Jaguar8

2 hours ago

NEWS

$Syros Pharmaceuticals (SYRS.US)$
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
Syros Pharmaceuticals (NASDAQ:SYRS) announced that its SELECT-MDS-1 Phase 3 trial of tamibarotene combined with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression failed to meet its primary endpoint. The complete response rate in the treatment arm wa...